France’s highest administrative court, the Conseil d’Etat, has rejected attempts by Novartis and Roche to stop the use of Roche’s anticancer Avastin (bevacizumab) for the treatment of wet AMD, an unapproved indication, in place of Novartis’ Lucentis (ranibizumab), which is authorized for the condition but is much more expensive.
The court rejected the companies’ request to annul a “temporary use authorization” (RTU) issued by the regulatory body,...








